The Food and Drug Administration (FDA) granted full approval to Leqembi, an Alzheimer’s drug, on Thursday, July 6, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease.
This item is available in full to subscribers.
To continue reading, you will need to either log in to your subscriber account, below, or purchase a new subscription.
Please log in to continue
|
